Histogen Inc
Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its prec… Read more
Histogen Inc (HSTO) - Net Assets
Latest net assets as of September 2023: $4.40 Million USD
Based on the latest financial reports, Histogen Inc (HSTO) has net assets worth $4.40 Million USD as of September 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.82 Million) and total liabilities ($1.41 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.40 Million |
| % of Total Assets | 75.71% |
| Annual Growth Rate | -14.21% |
| 5-Year Change | -51.18% |
| 10-Year Change | N/A |
| Growth Volatility | 109.88 |
Histogen Inc - Net Assets Trend (2013–2022)
This chart illustrates how Histogen Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Histogen Inc (2013–2022)
The table below shows the annual net assets of Histogen Inc from 2013 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $13.38 Million | -33.74% |
| 2021-12-31 | $20.19 Million | +192.00% |
| 2020-12-31 | $6.91 Million | +118.21% |
| 2019-12-31 | $-37.97 Million | -238.57% |
| 2018-12-31 | $27.40 Million | -2.13% |
| 2017-12-31 | $28.00 Million | +28.49% |
| 2016-12-31 | $21.79 Million | -36.92% |
| 2015-12-31 | $34.54 Million | +3.99% |
| 2014-12-31 | $33.21 Million | -37.47% |
| 2013-12-31 | $53.12 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Histogen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 767891.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.03% |
| Other Components | $102.67 Million | 712.76% |
| Total Equity | $14.40 Million | 100.00% |
Histogen Inc Competitors by Market Cap
The table below lists competitors of Histogen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SAPPORO HOLDINGS
MU:SBW
|
$85.47K |
|
Marr SpA
BE:M6Z
|
$85.52K |
|
Active Energy Group PLC
PINK:ATGVF
|
$85.59K |
|
AMCJX
NMFQS:AMCJX
|
$85.65K |
|
Chesnara
LSE:CSN
|
$85.41K |
|
Homebiogas Ltd
TA:HMGS
|
$85.39K |
|
Bytes Technology Ltd
LSE:BYIT
|
$85.35K |
|
Goldman Sachs BDC Inc
NYSE:GSBD
|
$85.16K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Histogen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 21,192,000 to 14,405,000, a change of -6,787,000 (-32.0%).
- Net loss of 10,481,000 reduced equity.
- Dividend payments of 488,000 reduced retained earnings.
- Share repurchases of 488,000 reduced equity.
- New share issuances of 4,405,000 increased equity.
- Other factors increased equity by 265,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.48 Million | -72.76% |
| Dividends Paid | $488.00K | -3.39% |
| Share Repurchases | $488.00K | -3.39% |
| Share Issuances | $4.41 Million | +30.58% |
| Other Changes | $265.00K | +1.84% |
| Total Change | $- | -32.03% |
Book Value vs Market Value Analysis
This analysis compares Histogen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $7.22 | $0.03 | x |
| 2014-12-31 | $2.15 | $0.03 | x |
| 2015-12-31 | $1.86 | $0.03 | x |
| 2016-12-31 | $9.62 | $0.03 | x |
| 2017-12-31 | $9.79 | $0.03 | x |
| 2018-12-31 | $9.02 | $0.03 | x |
| 2019-12-31 | $-62.76 | $0.03 | x |
| 2020-12-31 | $17.43 | $0.03 | x |
| 2021-12-31 | $11.05 | $0.03 | x |
| 2022-12-31 | $4.49 | $0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Histogen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -72.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -278.08%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.32x
- Recent ROE (-72.76%) is above the historical average (-89.95%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -29.40% | 0.00% | 0.00x | 1.07x | $-20.93 Million |
| 2014 | -67.20% | 0.00% | 0.00x | 1.16x | $-25.64 Million |
| 2015 | -69.91% | 0.00% | 0.00x | 1.15x | $-27.60 Million |
| 2016 | -136.46% | -3721.10% | 0.01x | 3.78x | $-31.91 Million |
| 2017 | -62.14% | -49.17% | 0.43x | 2.93x | $-20.20 Million |
| 2018 | -65.73% | -53.62% | 0.69x | 1.78x | $-20.75 Million |
| 2019 | 0.00% | -43.33% | 3.84x | 0.00x | $-1.19 Million |
| 2020 | -327.91% | -1251.77% | 0.14x | 1.91x | $-26.56 Million |
| 2021 | -67.97% | -1567.46% | 0.03x | 1.29x | $-16.52 Million |
| 2022 | -72.76% | -278.08% | 0.20x | 1.32x | $-11.92 Million |
Industry Comparison
This section compares Histogen Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Histogen Inc (HSTO) | $4.40 Million | -29.40% | 0.32x | $85.44K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |